FDA Approved Device for Advanced Pancreatic Cancer

The wearable device demonstrated improved survival rates for patients receiving chemotherapy in a Phase 3 trial.

Updated on Sept. 28, 2026 in Cancer

Isometric editorial illustration of a portable medical device featuring geometric pads and connective cabling, representing advanced cancer treatment technology. — The FDA has approved Optune Pax, a portable, noninvasive device designed to deliver tumor-treating electric fields to patients with advanced pancreatic cancer. AI Illustration. Upload story photo >

Live Poll

Do you believe new medical devices should prioritize extending life over minimizing daily lifestyle disruption?

In February 2026, the FDA approved Optune Pax, a portable, noninvasive device that delivers tumor treating fields to the abdomen. It is indicated for use alongside standard chemotherapy for patients diagnosed with locally advanced pancreatic cancer.

Why it matters

This approval offers a new adjunctive option for patients managing locally advanced pancreatic cancer, as the device has shown potential to extend survival time and delay pain progression. By adding this noninvasive technology to standard care, patients may benefit from a combination approach that targets cancer cells differently than systemic chemotherapy alone.

In the PANOVA-3 Phase 3 trial of 571 patients, those using the Optune Pax device alongside chemotherapy saw a median overall survival of 16.2 months compared to 14.2 months for chemotherapy alone. This finding follows a 1:1 randomization protocol measuring survival benefit in the intent-to-treat population.

The players

FDA

The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and pharmaceuticals.

Optune Pax

A medical device that delivers noninvasive tumor treating fields to interfere with the cellular division of cancer cells in the abdomen.

The details

Optune Pax is a portable, noninvasive device that uses electric fields applied to the abdomen to disrupt cancer cell division. By interfering with the tumor microenvironment, these tumor treating fields work concurrently with gemcitabine and nab-paclitaxel to inhibit malignant growth. Patients generally tolerate the device well, with reported side effects primarily limited to mild grade 1 or 2 skin reactions.

February 2026: The FDA officially granted approval for the Optune Pax device.

Cancer
Sept. 22
FDA Approved New Pancreatic Cancer Drug
Cancer
Sept. 28
FDA Approved 16 New or Expanded Cancer Therapies
Cancer
Sept. 25
FDA Approved New Therapy for Bile Duct Cancer

Health Landscape

This approval follows the findings of the PANOVA-3 trial, which investigated the integration of electric-field therapy into standard pancreatic cancer treatment protocols. It represents a shift toward incorporating targeted bio-electrical devices into regimens previously dominated by systemic chemotherapeutic agents.

Patients currently receiving chemotherapy for locally advanced pancreatic cancer should consult their oncologist about whether this device is a suitable addition to their treatment plan. Discussing potential side effects, such as skin reactions, is a critical step in determining if this noninvasive tool aligns with your specific care goals.

The takeaway

The Optune Pax device introduces a noninvasive, chemotherapy-adjunct option that showed a modest survival benefit in a Phase 3 study. Patients navigating treatment for locally advanced pancreatic cancer should prioritize a discussion with their oncology team regarding the risks and clinical benefits of this technology.